Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Hepatic fibrosis: from bench to bedside.

Detlef Schuppan1, Yury Popov, Yury Porov

  • 1Department of Medicine I, Division of Gastroenterology, Hepatology and Infectiology, University of Erlangen-Nuernberg, Germany. detlef.schuppan@med1.med.uni-erlangen.de

Journal of Gastroenterology and Hepatology
|December 11, 2002
PubMed
Summary

Targeting activated liver cells with antifibrotic therapies shows promise. Novel drug delivery and receptor blockade strategies offer potential for effective, individualized liver fibrosis treatment.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

In Vitro TLR4 Stimulating Bioactivities of Amylase/Trypsin-Inhibitors from Wheat (<i>Triticum aestivum</i> L.) Bred from 1891 to 2010.

Foods (Basel, Switzerland)·2026
Same author

Erratum to 'Hot and cold fibrosis: The role of serum biomarkers to assess immune mechanisms and ECM-cell interactions in human fibrosis' [J Hepatol 83 (2025) 239-257].

Journal of hepatology·2026
Same author

Upcoming Treatments in Celiac Disease: From Luminal Enzymes to Oral Immune Tolerance.

United European gastroenterology journal·2026
Same author

Therapeutic TG2 inhibition reverses systemic multiomic dysregulation in celiac disease.

BMC medicine·2026
Same author

Sex-related differences in cardiovascular inflammation and metabolomics in a humanized transgenic mouse model of celiac disease.

Scientific reports·2026
Same author

ECM1 produced by hepatic stellate cells serves as a gatekeeper of liver homeostasis in hepatic fibrosis.

Hepatology (Baltimore, Md.)·2026

Area of Science:

  • Hepatology
  • Pharmacology
  • Cell Biology

Background:

  • Liver fibrosis involves activated hepatic stellate cells and fibroblasts excessively synthesizing matrix proteins.
  • Cell activation is driven by fibrogenic factors and mechanical stress, with limited in vivo therapeutic success.

Purpose of the Study:

  • To review current and emerging antifibrotic therapies for liver fibrosis.
  • To explore novel strategies for targeting fibrogenic liver cells and reversing fibrosis.

Main Methods:

  • Review of existing antifibrotic agents (e.g., silymarin, pentoxifylline, endothelin-A-receptor inhibitors).
  • Discussion of emerging strategies including cytokine inhibition (TGF-beta) and targeted drug delivery via cyclic peptides.
  • Exploration of receptor blockade to induce fibrolytic phenotypes.

Related Experiment Videos

Main Results:

  • Several agents show antifibrotic effects in vitro, with limited in vivo translation.
  • Plant-derived compounds, phosphodiesterase inhibitors, and endothelin-A-receptor antagonists have demonstrated antifibrotic effects.
  • Targeted drug delivery and receptor blockade represent promising new avenues for antifibrotic therapy.

Conclusions:

  • Effective antifibrotic therapies require targeting activated fibrogenic cells in the liver.
  • Novel strategies like targeted drug delivery and receptor blockade offer potential for individualized treatment.
  • Validation of serological markers will aid in personalized management of liver fibrosis.